All In Biotech

Free tool

FAERS Monitor: Ssd Af

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018578 or its brand name (Ssd Af, Silver Sulfadiazine). Reports on generic versions are filed under their own applications.

Reports

1,422

Serious

942

66% of reports

Hospitalization

483

Death reported

177

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication133
  • off label use114
  • pain97
  • fatigue87
  • chronic kidney disease86
  • drug ineffective77
  • death73
  • diarrhoea68
  • acute kidney injury66
  • nausea66
  • anxiety63
  • pneumonia63
  • rash60
  • renal failure58
  • fall55

Reports by year received

View as table
YearReports
20049
200514
200611
200716
20084
200917
201014
201117
201235
201324
201432
201537
201679
201777
2018107
2019119
2020126
2021176
2022127
2023114
202488
202585
202693

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,737 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal8616.813.71,262
product use in unapproved indicationSignal1337.96.8809
renal failureSignal586.55.0264
acute kidney injurySignal666.45.0296
anxietySignal633.32.699
pneumoniaSignal632.92.377
fallSignal552.41.946
painSignal972.31.975
rashSignal602.01.631
off label use1141.91.652
fatigue871.71.323
diarrhoea681.61.213
death731.31.04
nausea661.21.03
drug ineffective770.90.72

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.